Vittorio Fusco, Massimo Di Maio, Anna Amela Valsecchi, Daniele Santini, Marcello Tucci, Ugo De Giorgi, Paolo Bossi, Toni Ibrahim, Luigi Cavanna, Gaetano Lanzetta, Maura Rossi, Giorgia Rossetti, Mario Airoldi, Alessandro Comandone, Saverio Cinieri
PURPOSE: Optimal use of bone-modifying agents (BMAs) in patients with bone metastases from solid tumors is uncertain in some aspects: the drug choice; the planned treatment duration and long-term therapy; the prevention and management of possible side effects, including renal toxicity, hypocalcaemia, and medication-related osteonecrosis of the jaw (MRONJ). METHODS: Italian oncologists were invited to fulfil a 24-question web survey about prescription of BMAs for bone metastases of breast cancer, prostate cancer, and other solid tumors...
March 1, 2024: Supportive Care in Cancer